开发肿瘤靶向三特异性抗体！吉利德(GILD.US)与Merus达成超15亿美元合作

智通财经03-07

智通财经APP获悉，3月6日，吉利德(GILD.US)宣布与Merus(MRUS.US)达成合作，双方将共同开发多款靶向新型肿瘤相关抗原(TAA)的三特异性抗体。根据协议，Merus需将选定的两个项目推行至目标阶段，并可选择性开展第三个项目。吉利德将负责选定项目的额外研究、开发和商业化活动，即权益锁定。一旦行权，Merus将获得5600万美元的首付款以及2500万美元的股权投资，潜在交易金额超15...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2417766651?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-03-07 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2417766651","market":"us","top_or_hot":-1,"title":"开发肿瘤靶向三特异性抗体！吉利德(GILD.US)与Merus达成超15亿美元合作","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3月6日，吉利德(GILD.US)宣布与Merus(MRUS.US)达成合作，双方将共同开发多款靶向新型肿瘤相关抗原(TAA)的三特异性抗体。根据协议，Merus需将选定的两个项目推行至目标阶段，并可选择性开展第三个项目。吉利德将负责选定项目的额外研究、开发和商业化活动，即权益锁定。一旦行权，Merus将获得5600万美元的首付款以及2500万美元的股权投资，潜在交易金额超15...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1083157.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>开发肿瘤靶向三特异性抗体！吉利德(GILD.US)与Merus达成超15亿美元合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n开发肿瘤靶向三特异性抗体！吉利德(GILD.US)与Merus达成超15亿美元合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-07 21:26 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1083157.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月6日，吉利德(GILD.US)宣布与Merus(MRUS.US)达成合作，双方将共同开发多款靶向新型肿瘤相关抗原(TAA)的三特异性抗体。根据协议，Merus需将选定的两个项目推行至目标阶段，并可选择性开展第三个项目。吉利德将负责选定项目的额外研究、开发和商业化活动，即权益锁定。一旦行权，Merus将获得5600万美元的首付款以及2500万美元的股权投资，潜在交易金额超15...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1083157.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2087621335.USD","symbol_name":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1083157.html","article_id":"2417766651","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2417766651","pubTimestamp":1709817992,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，3月6日，吉利德宣布与Merus达成合作，双方将共同开发多款靶向新型肿瘤相关抗原的三特异性抗体。一旦行权，Merus将获得5600万美元的首付款以及2500万美元的股权投资，潜在交易金额超15亿美元。Merus官网公示的管线中均为双抗产品。2016年，Incyte与Merus就11个双特异性抗体达成合作。Incyte将支付1.2亿美元的预付款，并购买Merus8000万美元的普通股。此外，Merus还与礼来、先声药业、贝达药业等药企均有合作。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4588":"碎股","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4583":"猴痘概念","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","GILD":"吉利德科学","BK4532":"文艺复兴科技持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4566":"资本集团","BK4568":"美国抗疫概念","BK4578":"CAR-T","LU0058720904.USD":"联博国际健康护理基金A","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4550":"红杉资本持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC"},"translate_title":"Develop tumor targeting three specific antibodies! GILD.US and Merus reached a cooperation of over 1.5 billion US dollars","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"智通财经APP获悉，3月6日，吉利德(GILD.US)宣布与Merus(MRUS.US)达成合作，双方将共同开发多款靶向新型肿瘤相关抗原(TAA)的三特异性抗体。根据协议，Merus需将选定的两个项目推行至目标阶段，并可选择性开展第三个项目。吉利德将负责选定项目的额外研究、开发和商业化活动，即权益锁定。一旦行权，Merus将获得5600万美元的首付款以及2500万美元的股权投资，潜在交易金额超15亿美元。此次合作，是吉利德继Tentarix之后的又一次多抗布局。两笔交易主体均为多个临床前项目，Tentarix则将获得6600万美元的股权融资。Merus官网公示的管线中均为双抗产品。2016年，Incyte与Merus就11个双特异性抗体达成合作。Incyte将支付1.2亿美元的预付款，并购买Merus8000万美元的普通股。此外，Merus还与礼来、先声药业、贝达药业等药企均有合作。先声药业获得三款双特异性抗体的中国权益，贝达药业获得MCLA-129(EGFR×c-MET)的中国权益。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2417766651"}